Potential of Taming MicroRNA on Driver Seat to Control Mitochondrial Horses in Breast Carcinoma

Breast cancer among women is one of the most common carcinomas worldwide. Compared to developed countries, the breast cancer cases reported in India have boosted rapidly. At the same time, alarming statistics show that ratio of mortality cases over the total incidences is significantly high in comparison to developed world (Global Heath Estimates, WHO 2015). In recent times, several oncogenic signaling pathways have shown convergent effects on various types of cancer cell metabolism including breast cancer leading to tumor development. In 1931, German biochemist Otto Warburg revealed that cancer cells burn sugar (glycolysis) differently than normal cells. Cancer cells prefer to burn sugar over energy rich fats even when cellular oxygen conditions favor mitochondrial fat burning. Further, Warburg hypothesized that cancer is caused by mitochondrial dysfunction forcing the cells to use aerobic glycolysis instead of oxidative phosphorylation (OXPHOS). MicroRNAs (miRNAs) are critical classes of small ~22 nt non-coding endogenous RNAs implicated in gene expression regulation. To date, miRNAs have shown to regulate many cellular metabolic pathways critical for breast carcinoma patho-physiology. There is common consent that miRNAs dedicated to mitochondria and cellular metabolism have profound positive effects on breast carcinoma survival and metastasis. Therefore, in future there is huge scope for identification of miRNA types playing as a driver in mitochondria for breast tumor development. Further, several strategies to taming as well as knocking down these miRNA in breast tumor would be one of the fascinating approaches in medical sciences and cancer therapy. Here, we review updated scientific findings and possible therapeutic interventions with reference to miRNAs, mitochondria, cellular metabolism and breast carcinoma.